Oral Anticoagulant Edoxaban Alternative for Cancer-Related Thromboembolism

No abstract available
Source: Oncology Times - Category: Cancer & Oncology Tags: News Source Type: research

Related Links:

Conclusions The presence of comorbidities was linked to NOAC use over vitamin K antagonist, which is different from prescription factor studies in other countries and requires further study.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
AbstractMalignancy is a well-established risk factor for venous thromboembolism and while low-molecular-weight heparin therapy has been standard of care for cancer-associated thrombosis for many years, many patients find injection therapy burdensome. The direct oral anticoagulant edoxaban has been shown to be noninferior to dalteparin for the treatment of cancer-associated thrombosis. In a Markov simulation model, edoxaban with 6-month time horizon and a United States societal perspective with 2017 US dollars, edoxaban was the preferred strategy in the general cancer population (6-month cost $6061 with 0.34 quality adjuste...
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
Abstract Venous thromboembolism (VTE) occurs in up to 30% of patients with cancer.1,2 Prior guidelines have recommended low molecular weight heparin (LMWH) for 3-6 months as first-line therapy in cancer patients with newly-diagnosed VTE.3-5 Unfortunately, LMWH is associated with poor compliance due to the need for subcutaneous injection.6,7 Direct oral anticoagulants (DOACs) have been increasingly used for the treatment of VTE, are administered orally with no requirement for regular laboratory monitoring, and may have fewer drug-drug interactions as compared with warfarin, despite DOACs possessing a greater cost c...
Source: Accident and Emergency Nursing - Category: Emergency Medicine Authors: Tags: Acad Emerg Med Source Type: research
AbstractAcutely ill medical patients with cancer are at increased risk of venous thromboembolism (VTE). Thromboprophylaxis is recommended in the presence of cancer, but its safety is not known. The aim of this study was to assess the efficacy and safety of extended prophylaxis with betrixaban in cancer patients enrolled in the APEX trial. APEX was a randomized, double-blind trial comparing oral betrixaban 80  mg qd administered for 35–42 days with subcutaneous enoxaparin 40 mg qd administered for 10 ± 4 days. Patients with acute medical illness and a history of cancer or activ...
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
Conclusions: Patients who experienced recurrent VTE had 6.6-fold higher mortality rate than patients with no recurrences. The presence of active cancer was not a statistically significant risk factor for recurrence when taking into account the competing risk of death. Duration and drug class of anticoagulation did not seem to impact recurrence rate. PMID: 31438542 [PubMed - in process]
Source: Medicina (Kaunas) - Category: Universities & Medical Training Authors: Tags: Medicina (Kaunas) Source Type: research
CONCLUSIONS: Low-dose DOAC reduces the rate of overall VTE in higher-risk cancer patients starting systemic chemotherapy. It may reduce the rate of symptomatic VTE but increase the likelihood of bleeding. This article is protected by copyright. All rights reserved. PMID: 31420937 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Tags: J Thromb Haemost Source Type: research
AbstractThere are no guideline recommendations for the use of anticoagulant therapy in atrial fibrillation (AF) patients with cancer, which creates uncertainty about the optimal antithrombotic treatment in these patients. We conducted a network meta-analysis for the first time to assess the efficacy and safety of anticoagulant drugs in patients with AF and concurrent cancer. The PubMed, EMBASE, and Cochrane databases were searched up to March 2019. A search was made for the main anticoagulant drugs (warfarin, dabigatran, apixaban, rivaroxaban, and edoxaban). Outputs were presented as odds ratios (ORs), their corresponding ...
Source: Heart Failure Reviews - Category: Cardiology Source Type: research
Semin Thromb Hemost DOI: 10.1055/s-0039-1693473Data regarding the effect of coagulation proteins on enhancing angiogenesis and tumor growth are ample. Thus, inhibition of the coagulation system in an attempt to reduce tumor growth and metastasis seems appealing. However, such molecules as direct oral anticoagulants, warfarin and heparins, may impose a bleeding tendency, limiting the treatment dose that can be used. The heparanase protein, as a cofactor for tissue factor (TF) activity, enhances activation of the coagulation system and in addition has several nonhemostatic effects increasing tumor growth. The molecules curre...
Source: Seminars in Thrombosis and Hemostasis - Category: Hematology Authors: Tags: Review Article Source Type: research
Semin Thromb Hemost DOI: 10.1055/s-0039-1693479Cancer-associated thrombosis (CAT) is a common occurrence in the journey of a cancer patient and its management poses significant challenges. Low molecular weight heparin (LMWH) is the standard of care but the high cost and the inconvenience of daily injections have led to low persistence with therapy. Direct oral anticoagulants (DOACs) are effective and safe for the treatment of venous thromboembolism (VTE) compared with vitamin K antagonist (VKA) therapy in noncancer patients, and emerging data comparing their use with LMWH in CAT are rapidly changing clinical practice. Rece...
Source: Seminars in Thrombosis and Hemostasis - Category: Hematology Authors: Tags: Review Article Source Type: research
Researchers have spent many years developing improved medical treatments for pulmonary embolism (PE), such as development of the direct oral anticoagulants, outpatient management of PE and optimization of treatments for cancer-associated PE. Much of this research has focused on reducing venous thrombotic recurrence and reducing bleeding complications, with success measured in terms of absolute risk reduction. Evidence-based medicine assumes that reduction in a measurable untoward outcome translates into improved patient-centered care.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Editorial Source Type: research
More News: Cancer | Cancer & Oncology | Oral Cancer | Thrombosis